BACKGROUND: Genetic studies have shown a possible relationship between the @entity48380 polymorphism in @entity15556 and the risk of @entity2 . However, the results have been conflicting. Thus we rigorously conducted a meta-analysis to clarify any association. MATERIALS AND METHODS: A total of 10 case-control studies involving 17,962 @entity2 cases and 77,216 control subjects were analysed. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of the association. RESULTS: We found the @entity15556 @entity48380 polymorphism to be associated with the risk of @entity2 (AA vs GG: OR=1.60, 95%CI=1.51-1.71). On stratified analysis by smoking status, a statistically significant increased risk was observed in the smoking group (AA vs GG: OR=1.80, 95%CI=1.61-2.01). However, this polymorphism was not associated with @entity2 risk in Asians (AA vs GG: OR=0.95, 95%CI=0.35-2.59), whereas it was linked to increased risk of @entity2 among Caucasians (AA vs GG: OR=1.65, 95%CI=1.55-1.76). CONCLUSIONS: Our meta-analysis provided statistical evidence for a strong association between @entity48380 polymorphism and the risk of @entity2 , especially in smokers and Caucasians. Application of this relationship may contribute to identification of individuals at high risk of @entity2 and indicate a chemoprevention target.

XXXX @entity48380 Polymorphism Association with Risk of Lung Cancer - Evidence from 17,962 Lung Cancer Cases and 77,216 Control Subjects.

@entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity15556 :: ('1138', 'Gene') :: ['CHRNA5'] @entity48380 :: ('rs16969968', 'SNP') :: ['rs16969968']
@entity15556 :: (1138,Gene) :: ['CHRNA5']
